Optimizing Rheumatology SMART on FHIR Prior Auth Workflows

The Challenge of Rheumatology Prior Authorization

Rheumatology practices face a significant prior authorization burden due to the chronic nature of conditions like rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS), which often necessitate high-cost biologic and targeted synthetic DMARDs. These therapies, including TNF-alpha inhibitors (e.g., adalimumab, etanercept) and non-TNF biologics (e.g., secukinumab, guselkumab), along with JAK inhibitors, require rigorous documentation and adherence to complex step therapy protocols. The ongoing need for re-authorization further strains administrative resources.

Common PA Triggers in Rheumatology

• Biologics: TNF-alpha inhibitors (Humira, Enbrel, Remicade, Cimzia, Simponi), IL-6, IL-17, IL-23 inhibitors, B-cell depletion agents, and specialty drugs like anifrolumab, belimumab, ustekinumab.
• JAK Inhibitors: Tofacitinib, baricitinib, upadacitinib, often requiring prior TNF inhibitor failure.
• Infusion Therapy: Provider-administered biologics that fall under the medical benefit.
• Advanced Imaging: MRI for inflammatory arthritis assessment and ultrasound-guided joint injections.
• DEXA Scans: For osteoporosis management in patients on chronic steroid therapy.

Leveraging SMART on FHIR for In-EMR Prior Auth

SMART on FHIR provides a standardized framework for launching prior authorization applications directly from within the EMR, eliminating the need for clinicians and coordinators to navigate separate portals. This integration means patient and encounter context is automatically transferred via SMART App Launch, enabling single sign-on via SMART OAuth 2.0. Klivira's platform uses FHIR R4 to read US Core resources from EMRs like Epic, Cerner, athenahealth, and MEDITECH, ensuring accurate and real-time clinical data access without manual transcription or screen-scraping.

Key Benefits of SMART on FHIR Workflow for Rheumatology

• Eliminates Context-Switching: Clinicians remain within their EMR's UI (e.g., Epic Hyperspace, Cerner PowerChart) when initiating and managing PAs.
• Automated Data Transfer: Patient demographics, diagnoses (ICD-10), and clinical notes are pulled directly from the EMR via FHIR, reducing manual data entry errors.
• Streamlined Documentation: Supports Da Vinci DTR for rendering questionnaires and populating them with EMR data, aligning with ACR Treatment Guidelines.
• Structured PA Submission: Utilizes Da Vinci PAS for electronic submission of prior authorization requests.
• Automated Status Updates: PA decisions and status changes are written back to the EMR as structured FHIR resources (DocumentReference, Communication, Task), ensuring the chart is always current.

Addressing Rheumatology-Specific Documentation and Step Therapy

Rheumatology prior authorizations are heavily reliant on specific clinical criteria and step therapy adherence. Payers often require detailed diagnosis documentation (e.g., 2010 ACR/EULAR criteria for RA, CASPAR criteria for PsA), disease activity assessments (DAS28, CDAI, BASDAI), and proof of prior conventional DMARD trials (e.g., methotrexate). Klivira's platform incorporates ACR-guideline-aware policy logic to guide users through these requirements, including biosimilar substitution mandates and specific step therapy sequences, which vary significantly between payers.

Mitigating Common Rheumatology PA Denial Reasons

• Step Therapy Not Completed: Ensures documentation of required prior agent trials in the correct sequence.
• Biosimilar Substitution Required: Guides towards compliant biosimilar usage per payer policies.
• Disease Activity Not Documented: Prompts for and pulls necessary scores like DAS28, CDAI, or PASI.
• Screening Documentation Gaps: Verifies completion of TB, hepatitis B/C screening, and immunization status before biologic initiation.
• Off-Indication Use: Validates requests against payer-specific policies for biologic use in various autoimmune conditions.

Klivira's Comprehensive Approach for Rheumatology Prior Auth

Klivira's platform provides a robust solution for rheumatology prior authorization by combining deep specialty-specific logic with advanced SMART on FHIR integration. From initial coverage discovery via Da Vinci CRD to structured documentation through Da Vinci DTR and electronic submission via Da Vinci PAS, Klivira ensures that the unique demands of rheumatology—including chronic re-authorization, medical vs. pharmacy benefit split routing, and pediatric-specific PA flows—are managed efficiently within the EMR. This results in reduced administrative burden and improved authorization turnaround times for critical therapies.